Abstract
Beta-blockers, previously considered contraindicated in heart failure are today amongst the most important drugs in heart failure. They improve survival and retard the need for cardiac transplantation. Since most clinical trials demonstrating the benefits of beta-blockers have been done in patients with mild to moderate heart failure, the use of these agents in patients with advanced heart failure remains contraindicated. In this brief review, the author theorizes that due to their immunomodulatory effects, beta-blockers may also play a helpful role in patients presenting cardiogenic shock related to septic shock. However, intensivists should keep in mind that no clinical data are available so far on the role of beta-blockers in septic cardiac shock. Thereby, because the use of beta-blockers in this setting is not established, nor recommended, it should only be applied under controlled trial conditions.
Keywords: Circulatory shock, cardiomyopathy, cardiac depression, anti inflammatory
Current Drug Therapy
Title: Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Volume: 1 Issue: 2
Author(s): Karim Bendjelid
Affiliation:
Keywords: Circulatory shock, cardiomyopathy, cardiac depression, anti inflammatory
Abstract: Beta-blockers, previously considered contraindicated in heart failure are today amongst the most important drugs in heart failure. They improve survival and retard the need for cardiac transplantation. Since most clinical trials demonstrating the benefits of beta-blockers have been done in patients with mild to moderate heart failure, the use of these agents in patients with advanced heart failure remains contraindicated. In this brief review, the author theorizes that due to their immunomodulatory effects, beta-blockers may also play a helpful role in patients presenting cardiogenic shock related to septic shock. However, intensivists should keep in mind that no clinical data are available so far on the role of beta-blockers in septic cardiac shock. Thereby, because the use of beta-blockers in this setting is not established, nor recommended, it should only be applied under controlled trial conditions.
Export Options
About this article
Cite this article as:
Bendjelid Karim, Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?, Current Drug Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488506776930941
DOI https://dx.doi.org/10.2174/157488506776930941 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry MicroRNAs in Breast Cancer: One More Turn in Regulation
Current Drug Targets The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease
Current Vascular Pharmacology Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Ultrasonographic Assessment of Cirrhosis and Portal Hypertension
Current Medical Imaging Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Dynamic Ventricular Repolarisation: From Physiology to Prognosis
Current Cardiology Reviews Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology Ansamycin Inhibitors of Hsp90: Natures Prototype for Anti-Chaperone Therapy
Current Topics in Medicinal Chemistry The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Synergistic Antimicrobial Activity of Combinations of Sanguinarine and EDTA with Vancomycin Against Multidrug Resistant Bacteria
Drug Metabolism Letters Cardiovascular and Hematological Medicine in 2018 – Advances and Insights
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Diversity of Hydroxamic Acids: Part II. Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy Amiodarone Hepatotoxicity
Current Vascular Pharmacology The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry